Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Autosomal dominant Charcot-Marie-Tooth disease type 2I (CMT2I) is a form of axonal Charcot-Marie-Tooth disease, a peripheral sensorimotor neuropathy, characterized by a late onset with severe sensory loss (paresthesia and hypoesthesia) associated with distal weakness, mainly of the legs, and absent or reduced deep tendon reflexes.
Features include: Hyporeflexia, Axonal degeneration/regeneration, Steppage gait, and Pes cavus and 6 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 2 | Hyporeflexia, Steppage gait |
Muscles |
MPZ encodes myelin protein zero (248 aa). Is an adhesion molecule necessary for normal myelination in the peripheral nervous system. It mediates adhesion between adjacent myelin wraps and ultimately drives myelin compaction Highest expression in Nerve Tibial (5,301 TPM) and Colon Sigmoid (33.9 TPM).
Charcot-Marie-Tooth disease type 2I is associated with mutations in the MPZ gene on chromosome 1.
The MPZ protein participates in MPZ gene:EGR2:SOX10:SMARCA4, MPZ gene expression, and EGR2, SOX10 and SMARCA4 bind the MPZ gene pathways.
MPZ is classified as a druggable target (Druggable Genome category) with score 0.0.
Genetic testing for MPZ is available. Testing is considered confirmatory for diagnosis.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
2 clinical trials registered, 2 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
3 publications have been identified in PubMed for Charcot-Marie-Tooth disease type 2I. Research spans Basic Science / Preclinical (67%) and Case Report / Case Series (33%).
Liu M (2026). [PMID: 41391004](https://pubmed.ncbi.nlm.nih.gov/41391004/). *Aging Cell*. [Basic Science / Preclinical]
Maino A (2025). [PMID: 41363019](https://pubmed.ncbi.nlm.nih.gov/41363019/). *J Peripher Nerv Syst*. [Case Report / Case Series]
Sisto A (2025). [PMID: 39698979](https://pubmed.ncbi.nlm.nih.gov/39698979/). *Autophagy*. [Basic Science / Preclinical]
Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 6:47 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Charcot-Marie-Tooth disease type 2I
2
Upper limb muscle weakness, Distal muscle weakness |
Arms and legs | 1 | Upper limb muscle weakness |